Mohacsy's Safe Portfolio Member Forum : OK, that made me laugh out loud. You wou...

santafe2 · 2025-04-04T18:22:54.1700000Z

OK, that made me laugh out loud. You wouldn't want anyone to ruin the fine reputation of a payment mechanism and meme based investment primarily used for drugs, financial scams, human trafficking and illegal arms sales. Why sir, I shall slap you across the face with my glove for the mere inference. LOL!!!!

Play Episode

6min

Proactive - Interviews for investors

NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton, Connecticut, conducts all of its research and development in-house, which insulates the company from international tariff fluctuations and supply chain disruptions. At the center of the company’s pipeline is NV-387, a broad-spectrum antiviral drug that differs from vaccines in both function and strategy. Rather than targeting specific viral strains, NV-387 works by mimicking the receptor sites used by over 90% of pathogenic viruses—including influenza, RSV, COVID-19, and smallpox. Vyas explained that this approach helps circumvent the problem of viral mutation, which often renders traditional vaccines less effective. “Regardless of how they mutate, they land on the same receptor site. So we copy the receptor site, which is invariant to mutation,” she said, underscoring the robustness of the NanoViricides platform. She also highlighted supportive regulatory developments in the U.S., noting that the new HHS administration has endorsed a more integrated approach to pandemic preparedness, which includes therapeutics like NV-387 as a key component. In light of recent USDA funding initiatives aimed at combating H5N1 avian flu, Vyas said the company is keen to explore applications of NV-387 in that space as well. Currently, NanoViricides is conducting a Phase 2 clinical trial targeting smallpox, following successful Phase 1 results with no reported adverse effects. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc NV387 #BroadSpectrumAntiviral #BiotechStocks #AntiviralTherapeutics #SmallpoxTreatment #BirdFlu #RSV #COVID19Treatment #ProactiveInvestors #PharmaInnovation #MeetaVyas #HHS #PandemicPreparedness

Proactive - Interviews for investors

Andromeda Metals nears funding milestone for Great White Project

Andromeda Metals Ltd acting CEO Sarah Clarke talked with Proactive about the company's progress on its flagship Great White Project in South Australia. Clarke outlined how the company is nearing a critical funding milestone, having entered into exclusive negotiations with Merricks Capital for a debt financing facility of up to $75 million. She explained that this follows detailed due diligence and represents a significant advancement in the project’s development. She noted that the facility would cover capitalised interest, fees, and a cost overrun tranche, with exclusivity on negotiations running through to the end of July. Clarke also said Andromeda is pursuing the balance of required funds through a parallel equity or investment process. The Great White Project is a high-grade kaolin operation targeting premium ceramic markets and sustainable concrete products. The company has all key approvals in place, feasibility studies completed, long-lead items ordered, and binding offtake agreements secured for its Stage 1A+ development, which involves 100,000 tonnes of kaolin production per annum. Clarke said the project team is fully mobilised, working across both operational readiness and financing, to ensure rapid commencement of construction once funding is secured. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #AndromedaMetals #GreatWhiteProject #Kaolin #MiningAustralia #CriticalMinerals #CeramicsIndustry #GreenConcrete #ProjectFinancing #MerricksCapital #ProactiveInvestors

Proactive - Interviews for investors

Switch Metals eyes fast-track tantalum output in Côte d'Ivoire as it lists on AIM

Switch Metals Plc (AIM:SWT) CEO Karl Akueson talked with Proactive's Stephen Gunnion about the company’s listing on London’s AIM market and its focus on developing tantalum projects in Côte d'Ivoire. Akueson explained that Switch Metals, a private company he founded, was acquired through a reverse takeover by Oneiro Energy. The company's flagship Issia project hosts tantalum mineralisation, including occurrences of coltan at surface. According to Akueson, this provides an opportunity for near-term production from shallow deposits, with the company aiming to reach output within the next two years. He described tantalum as “a very strategic technology metal… in our mobile phones, laptops, plasma TV, everything we use daily,” highlighting its importance and rarity. Akueson emphasised that 60% of the global supply currently comes from the DRC and Rwanda, and Switch Metals aims to become a significant alternative source. Discussing the decision to list in the UK, Akueson pointed to his personal background and the UK’s long-standing understanding of African production. The £2 million fundraise will support resource definition work at Issia, with plans to quickly define a resource and develop economic parameters to demonstrate value. “Tantalum is probably one of the most critical [metals], and a metal that is unique,” Akueson noted. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #Tantalum #SwitchMetals #CotedIvoireMining #CriticalMinerals #AIMListing #JuniorMining #ResourceDefinition #Coltan #TechMetals #ProactiveInvestors

Proactive - Interviews for investors

How Beforepay’s AI model drives strong returns

Beforepay Group Ltd Finance Manager Shreya Prakash talked with Proactive about the company’s dual focus on domestic consumer lending and enterprise software through its Carrington Labs division. She explained that Beforepay’s core product—a pay advance offering—provides short-term loans with a fixed 5% fee and no hidden costs, aiming to support Australians with transparent and ethical lending. Prakash said, “The most common reason people borrow from us is not because they want to go for a vacation... but to tide them over that short-term cash flow pinch.” She highlighted that this flagship product, launched in 2020, remains central to the business and differentiates itself through its ethical model and efficient cost structure. Carrington Labs, the company’s AI and analytics arm, is productising the risk models that power Beforepay and expanding operations in the US. Prakash noted that the company is writing around 40,000 loans with just 50 staff, underlining a strong operational efficiency. Billy Cheung, also from the finance team, added that Beforepay became profitable in the first half of FY23. He reported revenue approaching A$20 million and net profit of A$2.8 million in H1 FY25. Notably, the company reduced net defaults from around 3% to just 1.1%, attributing this to improved credit risk models. Cheung also mentioned growth in personal loan offerings and continued investment into Carrington Labs. While Beforepay’s main focus remains on the Australian market, the company is actively expanding Carrington Labs internationally, particularly in the US. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #Beforepay #ASXB4P #FintechAustralia #EthicalLending #PayAdvance #CarringtonLabs #AIinFinance #ConsumerLending #PersonalFinance #FinancialWellbeing #InvestorUpdate #ProactiveInvestors #FinanceInterview #ASXStocks #FintechNews

Followers	23
Posts	13656
Boards Moderated	0
Alias Born	07/10/2003

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Go Ad-Free